Caption Management 13F: New $3.1M Stake in ACAD
A recent SEC filing reveals Caption Management bought a new stake of 120,877 shares in ACADIA Pharmaceuticals.
Reviewed by automated data checks against the source filing. How we make and check alerts
Caption Management opened a new position of 120,877 shares in ACADIA Pharmaceuticals Inc. ($ACAD), according to a 13F filing with the SEC dated May 15, 2026. It reported 120,877 shares worth $3.08 million at the end of the quarter.
Since the filing, $ACAD is down 1.4% after 1 week, down 0.6% after 1 month and down 10.7% to date (from the $21.40 close on May 15, 2026).
Find the original: Caption Management 13F filings on SEC EDGAR
ACAD
ACADIA Pharmaceuticals Inc.
Key Points
- Caption Management opened a new position in ACADIA Pharmaceuticals Inc. ACAD, acquiring 120,877 shares valued at about $3.08 million.
- ACADIA Pharmaceuticals shares trade around $25.50, positioned between its 52-week low of $19.69 and high of $30.96.
- Several Wall Street firms have updated their views on the biotech firm, including a recent price target adjustment from UBS.
Get $ACAD trade alerts by text
We text you when insiders, Congress or big funds trade $ACAD. Free.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated ACADIA Pharmaceuticals Inc. alert may contain errors. Disclosures
Caption Management Opens New Position in ACADIA Pharmaceuticals
Caption Management initiated a new position in ACADIA Pharmaceuticals Inc. (NasdaqGS: ACAD), acquiring 120,877 shares of the biotechnology company. According to its latest Form 13F filing with the SEC for the period ending May 15, 2026, the newly established holding carried an estimated value of $3.08 million based on a cost basis of $23.62 per share. Because 13F filings look backward at institutional holdings from the end of the reporting period, this filing may not reflect the investor's exact current share count today.
ACADIA Pharmaceuticals Stock Price Context
ACADIA Pharmaceuticals shares trade near $25.50. The stock has experienced a range over the past year, moving between a 52-week low of $19.69 and a 52-week high of $30.96. The company carries a price-to-earnings ratio of 11.84, with a forward P/E of 29.66.
Recent Analyst Ratings and Price Targets
Wall Street firms have continued to adjust their outlooks on the biotech firm following recent market developments. On October 13, 2026, UBS downgraded the stock to a Neutral rating and lowered its price target to $23.00 from $49.00. Earlier in the autumn, other firms weighed in with adjustments. On October 8, 2026, RBC Capital maintained its Outperform rating while shifting its target to $36.00 from $37.00. Deutsche Bank kept a Buy rating on September 25, 2026, moving its target to $31.00 from $38.00. On the same day, HC Wainwright & Co. maintained a Buy rating while adjusting its target to $33.00 from $37.00. Citizens also maintained a Market Outperform rating on September 25, 2026, setting its target at $33.00 down from $36.00. Overall, the stock holds a consensus Buy recommendation with a mean price target of $33.89 across 19 analyst opinions.
Inside ACADIA Pharmaceuticals Operations
ACADIA Pharmaceuticals Inc. focuses on developing and commercializing medicines aimed at treating neurological and rare diseases throughout North America. Based in San Diego, California, the company employs 796 people. Its treatments target specialized medical needs within the healthcare sector.
What to Watch Next for ACAD
Investors tracking Caption Management and ACADIA Pharmaceuticals should monitor upcoming institutional disclosures and corporate updates. The company's next earnings report is scheduled for November 4, 2026. As always, quarterly 13F reports provide a snapshot of past institutional activity rather than real-time trading data.
Related Filing Alerts
Source: Caption Management's 13F filing on $ACAD (May 15, 2026). 13F filings show holdings as of the end of the reporting quarter and may not reflect the fund's current position. Find the original filing: Caption Management 13F filings on SEC EDGAR. Written by software, not financial advice. How we make alerts